



Technology Pipeline

SMALL MOLECULE



Anschutz

Innovations



Where we are located

CU ANSCHUTZ MEDICAL CAMPUS

The University of Colorado Anschutz is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UHealth University of Colorado Hospital and Children's Hospital Colorado - that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, the CU Anschutz delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by over \$704 million in research grants.

For more information, visit www.cuanschutz.edu.



■ AVAILABLE ■ PARTNERED



Oncology/Hematology

PRINCIPAL INVESTIGATOR (PI)

Daniel LaBarbera	24-172	NEW CHD1L INHIBITORS (CHD1LI) FOR THE TREATMENT OF CANCER
Daniel LaBarbera	5158	CHD1L INHIBITORS
David Ross	1382	HSP90 INHIBITORS
Hatim Sabaawy	24-159	TARGETING RNA WITH SMALL MOLECULES
Heide Ford	5305	EYA2 ALLOSTERIC INHIBITORS - MEDULLOBLASTOMA
James Lambert	6186	PRL-3 - TNBC
John Stewart (deceased)	7066	BRADYKININ ANTAGONISTS




About our resources

CENTER FOR DRUG DISCOVERY

The University of Colorado Anschutz Center for Drug Discovery supports drug discovery and development of small molecules, peptides, proteins and antibody-based therapeutics through services like assay development, high-throughput and high-content screening, medicinal chemistry for each stage of development, and pharmacology, including PK, PD, and toxicology. Directed by Dr. Dan LaBarbera, the Center for Drug Discovery also offers additional unique models for microtissues and organoids through 2D and 3D printing as well as phenotypic cell painting.


**Translational
Phase:
From Discovery
to Bedside**



For more information, visit www.pharmacy.cuanschutz.edu/drug-discovery.

To see facility in the news, go to www.youtube.com/watch.

■ AVAILABLE ■ PARTNERED



Oncology/Hematology (cont.)

Lajos Gera	2399	FLURBIPROFEN BASED - NSCL	Partnered
Lajos Gera	2737	SILICON CONTAINING – PROSTATE AND LUNG CANCER	Partnered
Philip Reigan	3468	WEE1 KINASE INHIBITORS - GLIOBLASTOMA MULTIFORME	Available
Philip Reigan	4899	STAT3 INHIBITORS - AML	Available

Anesthesiology/Analgesic

Slobodan Todorovi	24-178	CAV3.2 INHIBITORS – ANALGESIC	Available
-------------------	--------	-------------------------------	-----------

Endocrine/Metabolism

Michael Wempe	5682	INHIBITORS OF FRUCTOSE METABOLISM	Partnered
MyPhuong Le	4278	FRUCTOKINASE INHIBITORS	Partnered
Timothy McKinsey	6289	HDAC11 INHIBITORS	Partnered

PRINCIPAL INVESTIGATOR (PI)



About our resources

COMPUTATIONAL CHEMISTRY & BIOLOGY CORE

The University of Colorado Anschutz Computational Chemistry and Biology Core Facility provides a wide array of advanced tools and services for computational-based simulations and modeling of chemical and biological systems. Located in the new Skaggs School of Pharmacy and Pharmaceutical Sciences building, the CCB Core offers specialized expertise to researchers in both academia and the biotech/pharmaceutical industry to develop and test hypotheses *in silico* before executing costly experimental methodologies, reduce the time and costs involved in cutting-edge research, target validation, and novel therapeutic development among other services.

For more information, visit www.pharmacy.cuanschutz.edu/research/core-facilities/computational-chemistry-and-biology-core-facility

■ AVAILABLE ■ PARTNERED



Immunology

George Eisenbarth

2757

AUTOIMMUNE THERAPY

Infectious Diseases

Andres F Vazquez-Torres

4379

DKSA - GRAM-NEGATIVE BACTERIA

Kambez Hajipouran Benam

4651

TYPE 2 TRANSMEMBRANE SERINE PROTEASES - INFLUENZA A

Ophthalmology

Ram Nagaraj

4371

ADVANCED GLYCATION ENDPRODUCTS - DIABETIC RETINOPATHY


Women's Health

T. Rajendra Kumar

5177

FSH ANTAGONISTS - OSTEOPOROSIS

PRINCIPAL INVESTIGATOR (PI)



About us

CU ANSCHUTZ INNOVATIONS

We bring together industry partners, entrepreneurs, and investors to help CU Researchers create biomedical technology that improves the quality of life worldwide. With expertise in patents, copyrights, and licensing, CU Anschutz Innovations translates discovery into impact through transparent, flexible, best practice intellectual property management services.

Located on University of Colorado Anschutz Medical Campus, Innovations provides access to an extensive portfolio of biomedical technologies, clinical validation opportunities, and resources for startup development.

Let's start a conversation.



CONTACT

David Wang
Assistant Director of BD & Licensing
CU Anschutz Innovations
University of Colorado Anschutz
david.d.wang@cuanschutz.edu




Anschutz

Innovations

Anschutz Health Sciences Building
1890 N. Revere Ct., Suite 6202
Aurora, CO 80045

(303) 724-3720
innovations@cuanschutz.edu

 [cuanschutz-innovations/](#)

 [@cuanschutz-innovations](#)



WEBSITE Scan to view our website and to learn more about how we can best support you >

cuanschutz.edu/innovations

